EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B

Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0324897 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Witchayaporn Praguylertluck und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Antiviral Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Songklanagarind Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tenofovir alafenamide (TAF) is recommended for chronic hepatitis B (CHB) treatment in international guidelines according to its efficacy and safety. However, in phase III study, an increased LDL-c was observed in those who were switched from Tenofovir disoproxil fumarate (TDF) to TAF. Limited data exists on whether lipid profiles change only in individuals who switched to TAF from TDF or from any nucleoside/nucleotide analogues (NUC). We investigated how switching to TAF affected lipid and cardiovascular outcomes in Thai CHB patients. Materials and methods We conducted a prospective observational study including CHB patients who had to switch from their prior NUC to TAF according to the national reimbursement policy in late 2022. All enrolled patients had lipid tests and transient elastography (TE) done at 0 and 48-week post-switch to TAF. Demographic data, prior NUC, liver biochemistry, controlled attenuated parameter (CAP) and liver stiffness (elastic modulus; E) data measured by TE were collected. The changes in lipid, Thai cardiovascular (CV) risk score, and TE results between 0 and 48-week were compared.

Results

A total of 110 patients who were switched to TAF and completed 48-week follow-up were analyzed. The prior NUCs were as follows: 47 Lamivudine (LAM), 22 Entecavir (ETV), and 41 TDF-based. Baseline characteristics were similar between the three groups except for underlying hypertension was more frequent and baseline total cholesterol was lower in the TDF-based group. At 48-week post-switch, the median LDL-c changes were -2.45, -5.9 and +8.8 mg/dL (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicTenofovirAntiviral AgentsCardiovascular DiseasesAdenineLipidsHumansMaleFemaleMiddle AgedAdultAlanineProspective StudiesHeart Disease Risk FactorsThailandDrug Substitution

Substanzen

Tenofovirtenofovir alafenamideAntiviral AgentsAlanineAdenineLipids

Autor:innen und Institutionen

  • Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
  • Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
  • NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand.

ORCID-Profile: Pimsiri Sripongpun

Förderung

  • Songklanagarind Hospital Foundation

Zitieren

APA

Praguylertluck, W., Kaewdech, A., Chamroonkul, N., Piratvisuth, T., & Sripongpun, P. (2025). Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B. PLOS One. https://doi.org/10.1371/journal.pone.0324897

Vancouver

Praguylertluck W, Kaewdech A, Chamroonkul N, Piratvisuth T, Sripongpun P. Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B. PLOS One. 2025. doi:10.1371/journal.pone.0324897

BibTeX
@article{Praguylertluck2025,
  author = {Praguylertluck, Witchayaporn and Kaewdech, Apichat and Chamroonkul, Naichaya and Piratvisuth, Teerha and Sripongpun, Pimsiri},
  title = {Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0324897}
}
Kostenlos starten →